IN THE CLAIMS

- 1-26. (canceled)
- 27. (currently amended) An *in vitro* method of treating a neoplastic cell, comprising: administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to a coding sequence for human MDM2 mRNA and which inhibit expression of MDM2 protein transcription or translation of a human MDM2 gene.
- 28. (original) The method of claim 27 wherein expression of the human MDM2 gene is inhibited by administering antisense oligonucleotides.
 - 29-55. (canceled)
- 56. (currently amended) An *in vitro* method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to a coding sequence for human MDM2 mRNA and which inhibit expression of human MDM2 protein transcription or translation of a human MDM2 gene.

- 57-61. (canceled)
- 62. (currently amended) An *in vitro* method of interfering with expression of MDM2 comprising administering to a neoplastic cell an antisense oligonucleotide which is complementary to a coding sequence for human MDM2 mRNA in an amount effective to interfere with expression of MDM2.

63. (currently amended) An *in vitro* method of interfering with expression of MDM2 comprising:

administering to a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein an antisense oligonucleotide which is complementary to a coding sequence for human MDM2 mRNA in an amount effective to interfere with expression of MDM2.